EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

PCSK9 inhibitors as safer therapeutics for atherosclerotic cardiovascular disease (ASCVD): Pharmacophore design and molecular dynamics analysis

Ibrahim O Kehinde, Oluwole Akawa, Adeniyi T Adewumi, Ali H Rabbad iD, Mahmoud E S Soliman iD

Journal of Cellular Biochemistry · 2024-07 · 125 (7)

DOI: 10.1002/jcb.30581 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular Biochemistry, online erschienen am 15.05.2024. Verfasst von Ibrahim O Kehinde und 4 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Bio-computation and Drug Design Laboratory, School of Health Sciences, University of KwaZulu-Natal, Westville Campus, Durban, South Africa. Hauptthemen laut MEDLINE: PCSK9 Inhibitors, Molecular Dynamics Simulation, Proprotein Convertase 9, Atherosclerosis. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cardiovascular disorders are still challenging and are among the deadly diseases. As a major risk factor for atherosclerotic cardiovascular disease, dyslipidemia, and high low‐density lipoprotein cholesterol in particular, can be prevented primary and secondary by lipid‐lowering medications. Therefore, insights are still needed into designing new drugs with minimal side effects. Proprotein convertase subtilisin/kexin 9 (PCSK9) enzyme catalyses protein‐protein interactions with low‐density lipoprotein, making it a critical target for designing promising inhibitors compared to statins. Therefore, we screened for potential compounds using a redesigned PCSK9 conformational behaviour to search for a significantly extensive chemical library and investigated the inhibitory mechanisms of the final compounds using integrated computational methods, from ligand essential functional group screening to all‐atoms MD simulations and MMGBSA‐based binding free energy. The inhibitory mechanisms of the screened compounds compared with the standard inhibitor. K31 and K34 molecules showed stronger interactions for PCSK9, having binding energy (kcal/mol) of −33.39 and −63.51, respectively, against −27.97 of control. The final molecules showed suitable drug‐likeness, non‐mutagenesis, permeability, and high solubility values. The C‐α atoms root mean square deviation and root mean square fluctuation of the bound‐PCSK9 complexes showed stable and lower fluctuations compared to apo PCSK9. The findings present a model that unravels the mechanism by which the final molecules proposedly inhibit the PCSK9 function and could further improve the design of novel drugs against cardiovascular diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PCSK9 InhibitorsMolecular Dynamics SimulationProprotein Convertase 9AtherosclerosisHumansDrug DesignCardiovascular DiseasesPharmacophore

Stichwörter der Autor:innen

binding free energy (MMGBSA)low‐density lipoprotein cholesterol (LDLC)per‐residue energy decompositionpharmacophoreproprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitorsstructural based virtual screening (SBVS)

Substanzen

PCSK9 InhibitorsPCSK9 protein, humanProprotein Convertase 9

Autor:innen und Institutionen

  • Molecular Bio-computation and Drug Design Laboratory, School of Health Sciences, University of KwaZulu-Natal, Westville Campus, Durban, South Africa.
  • Department of Pharmaceutical and Medicinal Chemistry, College of Pharmacy, Afe Babalola University, Ado-Ekiti, Nigeria.
  • Department of Life and Consumer Sciences, University of South Africa, Florida Campus, Johannesburg, South Africa.

ORCID-Profile: Ali H Rabbad, Mahmoud E S Soliman

Zitieren

APA

Kehinde, I. O., Akawa, O., Adewumi, A. T., Rabbad, A. H., & Soliman, M. E. S. (2024). PCSK9 inhibitors as safer therapeutics for atherosclerotic cardiovascular disease (ASCVD): Pharmacophore design and molecular dynamics analysis. Journal of Cellular Biochemistry, 125(7). https://doi.org/10.1002/jcb.30581

Vancouver

Kehinde IO, Akawa O, Adewumi AT, Rabbad AH, Soliman MES. PCSK9 inhibitors as safer therapeutics for atherosclerotic cardiovascular disease (ASCVD): Pharmacophore design and molecular dynamics analysis. Journal of Cellular Biochemistry. 2024;125(7). doi:10.1002/jcb.30581

BibTeX
@article{Kehinde2024,
  author = {Kehinde, Ibrahim O and Akawa, Oluwole and Adewumi, Adeniyi T and Rabbad, Ali H and Soliman, Mahmoud E S},
  title = {PCSK9 inhibitors as safer therapeutics for atherosclerotic cardiovascular disease (ASCVD): Pharmacophore design and molecular dynamics analysis},
  journal = {Journal of Cellular Biochemistry},
  year = {2024},
  volume = {125},
  number = {7},
  doi = {10.1002/jcb.30581}
}
Kostenlos starten →